Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK
Amgen and its partners at Novartis are one step closer to fielding a new migraine drug in the US. The pharma giants said Thursday afternoon …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
